This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Rx
AURLUMYN
10 mcg/ml, Roztwór do nebulizacji
INN: Iloprostum
Data updated: 2026-04-13
Available in:
🇨🇿🇩🇪🇬🇧🇫🇷🇵🇱🇵🇹🇸🇰🇺🇦
Form
Roztwór do nebulizacji
Dosage
10 mcg/ml
Route
wziewna
Storage
Unopened vials of AURLUMYN are stable until the date indicated on the package when stored at 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature] . The unopened vial should be kept in the carton and not exposed to direct sunlight. Do not freeze.
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
11 DESCRIPTION AURLUMYN contains iloprost, a synthetic analog of prostacyclin PGI 2 . The chemical name for iloprost is (5 E )-[3a S ,4 R ,5 R ,6a S )-5-hydroxy-4-[(1 E )-(3 S ,4 RS )-3-hydroxy-4-methyloct-1-en-6-ynyl]-hexahydropentalen-2(1 H )-ylidene]pentanoic acid. Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. Iloprost is an oily substance, which is soluble in methanol, ethanol, ethyl acetate, acetone, and pH 7 buffer, sparingly soluble in buffer pH 9, and very slightly soluble in distilled water, buffer pH 3, and buffer pH 5. The molecular formula of iloprost is C 22 H 32 O 4 and its molecular weight is 360.49. The structural formula is shown below: AURLUMYN (iloprost) injection is a clear, colorless, sterile solution formulated for intravenous use. AURLUMYN is supplied in single-use glass vials containing 1-mL per vial. Each mL of the solution contains 100 mcg (0.1 mg) of iloprost as the active ingredient and the following inactive ingredients: 8.1 mg ethanol, 9 mg sodium chloride, and 0.242 mg tromethamine. Hydrochloric acid and sodium hydroxide is added to adjust pH to 8.3. The solution contains no preservatives. Chemical Structure
⚠️ Warnings
For each inhalation session the content of one opened ampoule of iloprost has to be transferred completely into the medication chamber immediately before use.
After each inhalation session, any solution remaining in the nebuliser should be discarded. In addition, instructions for hygiene and cleaning of the nebulisers provided by the device manufacturers should be followed carefully.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.